Werewolf Therapeutics, Inc.

Contributing Author

Recent Articles by Werewolf Therapeutics, Inc.

May-29	Werewolf Therapeutics to Participate in the Upcoming Jefferies Global Healthcare Conference HOWL GlobeNewswire
May-20	HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124 HOWL GlobeNewswire
May-13	Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit HOWL GlobeNewswire
May-08	Werewolf Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update HOWL GlobeNewswire
May-05	Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting HOWL GlobeNewswire
May-05	Werewolf Therapeutics to Participate in Upcoming Investor Conferences HOWL GlobeNewswire